Abivax Sa ADR (ABVX)

$83.92 +1.05 (1.27%)
Market Cap 6.34B
Revenue (ttm) 0.00
Net Income (ttm) -190.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio -1.38
Volume 741,700
Avg Vol 1,138,576
Day's Range N/A - N/A
Shares Out 75.57M
Stochastic %K 62%
Beta 0.39
Analysts Strong Sell
Price Target $108.57

Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporat...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 53 83 09 63
Address:
7-11 boulevard Haussmann, Paris, France
Rickycello
Rickycello Oct. 5 at 5:24 PM
$ABVX https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect-trial
1 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 5 at 3:14 PM
$ABVX https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect-trial
0 · Reply
Doorhandle
Doorhandle Oct. 5 at 3:05 PM
$ABVX
0 · Reply
choppawontmiss
choppawontmiss Oct. 4 at 7:52 PM
$ABVX
0 · Reply
kshonstocks
kshonstocks Oct. 4 at 10:22 AM
$ABVX 99 A+ https://research.investors.com/stock-quotes/nasdaq-abivax-adr-abvx.htm
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 6:50 PM
$ABVX Outstanding article that hits the mark on ABVX's current state. So if you want to refresh your ABVX insights or learn about ABVX from scratch, this is a must read. https://beyondspx.com/quote/ABVX/analysis/abivax-a-new-era-for-ibd-treatment-with-differentiated-mir-124-enhancement-nasdaq-abvx
0 · Reply
Mr_Anderson007
Mr_Anderson007 Oct. 3 at 6:04 PM
$SLS The following is the chart just prior to $ABVX's jump to $60+ (now currently over $80). If you believe that Sellas is potentially deserving of a similar move then note how ABVX almost doubled just prior to their big move. Given the volume, it would appear that ABVX did not suffer the same extent as does Sellas given Sellas's massive warrant demon funding hold on the stock. If you want to play said risk/reward then basic investment theory suggests one must pay more for said opportunity!
2 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 3 at 3:01 PM
$SLS Manipulation is offering the Investment Opportunity of a Life time... Everyone knew the $ABVX P3 results were due - it Still Gapped up to $60 - from $5 days prior. This will be Happening Here. Likely Seeing the P3 Results This Month. $ABBV ADDED, $26B IN MARKET VALUE THE LAST 2 DAYS, ADDED. SLS $20B $101 Per Share, All In.
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 2 at 2:58 PM
$SRPT Skimmed some at 22, added a little $ABVX to balance port a bit
0 · Reply
elmono
elmono Oct. 2 at 2:55 PM
$VTYX UC hidden gem…..just like $PALI, $ABVX ahead….but expensive
0 · Reply
Latest News on ABVX
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Oct 5, 2025, 11:00 AM EDT - 9 hours ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Sep 29, 2025, 4:05 PM EDT - 6 days ago

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

Sep 23, 2025, 4:05 PM EDT - 12 days ago

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Sep 12, 2025, 11:45 AM EDT - 23 days ago

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Abivax Presents First Half 2025 Financial Results

Sep 8, 2025, 4:00 PM EDT - 27 days ago

Abivax Presents First Half 2025 Financial Results

How Hedge Funds Won Big on an Obscure Drugmaker

Aug 30, 2025, 5:30 AM EDT - 5 weeks ago

How Hedge Funds Won Big on an Obscure Drugmaker

2 Logical Mid-Cap Biotech Buyout Targets

Aug 27, 2025, 12:50 PM EDT - 5 weeks ago

2 Logical Mid-Cap Biotech Buyout Targets

MLTX

Abivax Announces Closing of $747.5 Million Public Offering

Jul 28, 2025, 4:15 PM EDT - 2 months ago

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Jul 25, 2025, 2:00 AM EDT - 2 months ago

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst

Jul 24, 2025, 4:20 PM EDT - 2 months ago

Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Jul 24, 2025, 8:40 AM EDT - 2 months ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Jul 24, 2025, 8:40 AM EDT - 2 months ago

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Jul 24, 2025, 1:30 AM EDT - 2 months ago

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax Announces Launch of Public Offering

Jul 23, 2025, 4:15 PM EDT - 2 months ago

Abivax Announces Launch of Public Offering

Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity

Jul 23, 2025, 3:10 PM EDT - 2 months ago

Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity

Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data Readout

Jul 19, 2025, 2:23 AM EDT - 2 months ago

Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data Readout

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Jun 11, 2025, 4:00 PM EDT - 4 months ago

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Abivax Presents First Quarter 2025 Financial Results

Jun 2, 2025, 4:00 PM EDT - 4 months ago

Abivax Presents First Quarter 2025 Financial Results

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

Jun 2, 2025, 11:00 AM EDT - 4 months ago

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

JNJ LLY

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Apr 29, 2025, 4:05 PM EDT - 5 months ago

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Apr 22, 2025, 4:05 PM EDT - 5 months ago

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Apr 22, 2025, 4:00 PM EDT - 5 months ago

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Mar 26, 2025, 5:05 PM EDT - 6 months ago

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax Announces Full Year 2024 Financial Results

Mar 24, 2025, 3:30 AM EDT - 6 months ago

Abivax Announces Full Year 2024 Financial Results

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Feb 21, 2025, 2:30 AM EST - 8 months ago

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Abivax Publishes 2025 Financial Calendar

Jan 28, 2025, 2:30 AM EST - 8 months ago

Abivax Publishes 2025 Financial Calendar

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Jan 23, 2025, 4:05 PM EST - 9 months ago

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Jan 9, 2025, 11:35 AM EST - 9 months ago

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Announces a Change to the Composition of its Board of Directors

Dec 23, 2024, 4:05 PM EST - 10 months ago

Abivax Announces a Change to the Composition of its Board of Directors

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Nov 19, 2024, 4:30 PM EST - 11 months ago

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax presents third quarter 2024 key financial information

Nov 14, 2024, 4:01 PM EST - 11 months ago

Abivax presents third quarter 2024 key financial information

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Nov 13, 2024, 4:01 PM EST - 11 months ago

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Oct 3, 2024, 4:01 PM EDT - 1 year ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Oct 3, 2024, 2:31 AM EDT - 1 year ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Sep 26, 2024, 2:30 AM EDT - 1 year ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Sep 25, 2024, 4:01 PM EDT - 1 year ago

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Abivax presents first-half 2024 financial results

Sep 9, 2024, 4:01 PM EDT - 1 year ago

Abivax presents first-half 2024 financial results

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Aug 6, 2024, 2:30 AM EDT - 1 year ago

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Abivax Provides Operational and Key Program Update

Jul 15, 2024, 4:00 PM EDT - 1 year ago

Abivax Provides Operational and Key Program Update

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

Jun 4, 2024, 4:10 PM EDT - 1 year ago

Abivax releases the results of its May 30, 2024 Ordinary and Extraordinary General Meeting

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

Apr 8, 2024, 1:25 PM EDT - 1 year ago

ABIVAX Société Anonyme (AAVXF) Q4 2023 Earnings Call Transcript

Abivax reports 2023 financial results and operational update

Apr 2, 2024, 2:30 AM EDT - 1 year ago

Abivax reports 2023 financial results and operational update

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

Feb 13, 2024, 2:50 AM EST - 1 year ago

Abivax Announces Presentation of Four Abstracts for Obefazimod in Ulcerative Colitis and Sponsorship of Scientific Symposium at The 19th Congress of European Crohn's and Colitis Organization (ECCO)

Citi Appointed as Depositary Bank for Abivax SA's ADR Program

Oct 26, 2023, 4:00 AM EDT - 2 years ago

Citi Appointed as Depositary Bank for Abivax SA's ADR Program

Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market

Oct 24, 2023, 4:15 PM EDT - 2 years ago

Abivax Announces Closing of its Initial Public Offering on the Nasdaq Global Market

U.S. IPO Weekly Recap: Big Launches And New Filings Keep The IPO Market Moving

Oct 21, 2023, 1:25 AM EDT - 2 years ago

U.S. IPO Weekly Recap: Big Launches And New Filings Keep The IPO Market Moving

HG JL MNR MVRK NCL WAY WBUY

Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris

Oct 20, 2023, 10:00 AM EDT - 2 years ago

Abivax Announces Trading Resumption of its Ordinary Shares on Euronext Paris

Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market

Oct 20, 2023, 9:15 AM EDT - 2 years ago

Abivax Announces the Pricing of its Initial Public Offering on the Nasdaq Global Market

Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Oct 20, 2023, 3:00 AM EDT - 2 years ago

Abivax Announces Temporary Trading Halt of its Ordinary Shares on Euronext Paris

Rickycello
Rickycello Oct. 5 at 5:24 PM
$ABVX https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect-trial
1 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 5 at 3:14 PM
$ABVX https://ir.abivax.com/news-releases/news-release-details/abivax-announces-late-breaking-presentation-8-week-abtect-trial
0 · Reply
Doorhandle
Doorhandle Oct. 5 at 3:05 PM
$ABVX
0 · Reply
choppawontmiss
choppawontmiss Oct. 4 at 7:52 PM
$ABVX
0 · Reply
kshonstocks
kshonstocks Oct. 4 at 10:22 AM
$ABVX 99 A+ https://research.investors.com/stock-quotes/nasdaq-abivax-adr-abvx.htm
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 6:50 PM
$ABVX Outstanding article that hits the mark on ABVX's current state. So if you want to refresh your ABVX insights or learn about ABVX from scratch, this is a must read. https://beyondspx.com/quote/ABVX/analysis/abivax-a-new-era-for-ibd-treatment-with-differentiated-mir-124-enhancement-nasdaq-abvx
0 · Reply
Mr_Anderson007
Mr_Anderson007 Oct. 3 at 6:04 PM
$SLS The following is the chart just prior to $ABVX's jump to $60+ (now currently over $80). If you believe that Sellas is potentially deserving of a similar move then note how ABVX almost doubled just prior to their big move. Given the volume, it would appear that ABVX did not suffer the same extent as does Sellas given Sellas's massive warrant demon funding hold on the stock. If you want to play said risk/reward then basic investment theory suggests one must pay more for said opportunity!
2 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 3 at 3:01 PM
$SLS Manipulation is offering the Investment Opportunity of a Life time... Everyone knew the $ABVX P3 results were due - it Still Gapped up to $60 - from $5 days prior. This will be Happening Here. Likely Seeing the P3 Results This Month. $ABBV ADDED, $26B IN MARKET VALUE THE LAST 2 DAYS, ADDED. SLS $20B $101 Per Share, All In.
0 · Reply
SannieVerraderlijk
SannieVerraderlijk Oct. 2 at 2:58 PM
$SRPT Skimmed some at 22, added a little $ABVX to balance port a bit
0 · Reply
elmono
elmono Oct. 2 at 2:55 PM
$VTYX UC hidden gem…..just like $PALI, $ABVX ahead….but expensive
0 · Reply
Ms_P
Ms_P Oct. 2 at 12:19 PM
$ABVX ABVX seems like a great way to get some European diversification in your portfolio
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 1 at 6:16 PM
$SLS $100K Invested in SLS today at $1.73 will be worth from $1M to $10M + when the GPs Phase 3 Results are Announced - sometime this quarter - could be any day now. The SLS launch will make $ABVX look minor... ... $5 to $90 in a week -- Gapped Up 600% to $60 and kept climbing after its phase 3 results were announced. ...
0 · Reply
HrSbdaddy
HrSbdaddy Oct. 1 at 12:26 PM
$ABVX Best shit stock in the France
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Oct. 1 at 4:56 AM
$SLS I expect after the T1 Halt. the Share Price will Gap Up at the Open to Just Shy of $5B in Market Value / about $40 Per Share --- and Continuing to Climb Very Similar to what Just Happened to $ABVX when they Announced their Phase 3 Trial Results, that everyone Knew were due. This $210M Baby Bio is about to release Phase 3 Trial data worth $20B to Big Pharma -- it is happening at some Point Soon - Results Worth Tens of Billions Are Inevitable. https://www.reddit.com/r/sellasLifescience/ $XBI $TSLA $BTC.X
0 · Reply
Zobzork
Zobzork Sep. 30 at 10:38 PM
$ABVX $NKTR $QURE Let's see which one ends up higher (by %) at the end of each month from this point
0 · Reply
whodat2025
whodat2025 Sep. 30 at 1:53 PM
$ABVX $GANX will this be the next big one. Parkinson’s trial data being released on MondaFingers crossed.y, October 6.
1 · Reply
biochirp
biochirp Sep. 30 at 1:51 PM
$ABVX LETS GOOOO
0 · Reply
highnihilism
highnihilism Sep. 30 at 8:34 AM
$AMT American Tower: 656 trades, $854K vs $1.16M avg (0.74x). $145K calls / $709K puts. $ABVX Abivax: 149 trades, $195K vs $190K avg (1.03x). $145K calls / $50K puts. $BDX Becton Dickinson: 94 trades, $181K vs $13.3M avg (0.01x !!!). $145K calls / $37K puts. $IOVA Iovance Biotherapeutics: 338 trades, $161K vs $420K avg (0.38x). $144K calls / $17K puts.
0 · Reply
Hello_AI
Hello_AI Sep. 30 at 6:55 AM
$MLTX , $ABVX
0 · Reply
diagio
diagio Sep. 29 at 10:37 PM
$QURE The problem with the short thesis here is you're treating this like a penny pharma garbage. Offering at $47.50 and it rips higher. Same as $ABVX with an offering at $64 and it ripped higher (and staying high). Stocks like this with huge over-subscribed offerings and big financial players behind you DONT SHORT.
2 · Reply
BanditQ
BanditQ Sep. 29 at 10:10 PM
$ABVX
0 · Reply
kshonstocks
kshonstocks Sep. 29 at 5:55 PM
$ABVX opening range breakout
0 · Reply